Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an...
7 insider purchases on record · latest filing 2020-02-03.
Insiders have also filed 241 sale transactions at ALEC.